These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12770925)

  • 1. The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors.
    Herold CL; Behm DJ; Buckley PT; Foley JJ; Wixted WE; Sarau HM; Douglas SA
    Br J Pharmacol; 2003 May; 139(2):203-7. PubMed ID: 12770925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.
    Behm DJ; Stankus G; Doe CP; Willette RN; Sarau HM; Foley JJ; Schmidt DB; Nuthulaganti P; Fornwald JA; Ames RS; Lambert DG; Calo' G; Camarda V; Aiyar NV; Douglas SA
    Br J Pharmacol; 2006 May; 148(2):173-90. PubMed ID: 16547525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist.
    Behm DJ; Herold CL; Ohlstein EH; Knight SD; Dhanak D; Douglas SA
    Br J Pharmacol; 2002 Oct; 137(4):449-58. PubMed ID: 12359626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors.
    Camarda V; Song W; Marzola E; Spagnol M; Guerrini R; Salvadori S; Regoli D; Thompson JP; Rowbotham DJ; Behm DJ; Douglas SA; Calo' G; Lambert DG
    Eur J Pharmacol; 2004 Sep; 498(1-3):83-6. PubMed ID: 15363979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new ligand for the urotensin II receptor.
    Camarda V; Guerrini R; Kostenis E; Rizzi A; Calò G; Hattenberger A; Zucchini M; Salvadori S; Regoli D
    Br J Pharmacol; 2002 Oct; 137(3):311-4. PubMed ID: 12237249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-II-induced contraction of cat isolated respiratory smooth muscle.
    Behm DJ; Ao Z; Camarda V; Aiyar NV; Johns DG; Douglas SA
    Eur J Pharmacol; 2005 Jun; 516(3):276-81. PubMed ID: 15975570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta.
    Patacchini R; Santicioli P; Giuliani S; Grieco P; Novellino E; Rovero P; Maggi CA
    Br J Pharmacol; 2003 Dec; 140(7):1155-8. PubMed ID: 14645137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.
    Douglas SA; Behm DJ; Aiyar NV; Naselsky D; Disa J; Brooks DP; Ohlstein EH; Gleason JG; Sarau HM; Foley JJ; Buckley PT; Schmidt DB; Wixted WE; Widdowson K; Riley G; Jin J; Gallagher TF; Schmidt SJ; Ridgers L; Christmann LT; Keenan RM; Knight SD; Dhanak D
    Br J Pharmacol; 2005 Jul; 145(5):620-35. PubMed ID: 15852036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity.
    Song W; McDonald J; Camarda V; Calo G; Guerrini R; Marzola E; Thompson JP; Rowbotham DJ; Lambert DG
    Naunyn Schmiedebergs Arch Pharmacol; 2006 May; 373(2):148-57. PubMed ID: 16596397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors.
    Behm DJ; Herold CL; Camarda V; Aiyar NV; Douglas SA
    Eur J Pharmacol; 2004 May; 492(2-3):113-6. PubMed ID: 15178353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urotensin-II receptor ligands. From agonist to antagonist activity.
    Grieco P; Carotenuto A; Campiglia P; Marinelli L; Lama T; Patacchini R; Santicioli P; Maggi CA; Rovero P; Novellino E
    J Med Chem; 2005 Nov; 48(23):7290-7. PubMed ID: 16279788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines.
    Douglas SA; Naselsky D; Ao Z; Disa J; Herold CL; Lynch F; Aiyar NV
    Br J Pharmacol; 2004 Jul; 142(6):921-32. PubMed ID: 15210573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists.
    Rossowski WJ; Cheng BL; Taylor JE; Datta R; Coy DH
    Eur J Pharmacol; 2002 Mar; 438(3):159-70. PubMed ID: 11909607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.
    Behm DJ; Harrison SM; Ao Z; Maniscalco K; Pickering SJ; Grau EV; Woods TN; Coatney RW; Doe CP; Willette RN; Johns DG; Douglas SA
    Br J Pharmacol; 2003 May; 139(2):464-72. PubMed ID: 12770952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay.
    Brkovic A; Hattenberger A; Kostenis E; Klabunde T; Flohr S; Kurz M; Bourgault S; Fournier A
    J Pharmacol Exp Ther; 2003 Sep; 306(3):1200-9. PubMed ID: 12807997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationship study on Tyr9 of urotensin-II(4-11): identification of a partial agonist of the UT receptor.
    Batuwangala M; Camarda V; McDonald J; Marzola E; Lambert DG; Ng LL; Calo' G; Regoli D; Trapella C; Guerrini R; Salvadori S
    Peptides; 2009 Jun; 30(6):1130-6. PubMed ID: 19463746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction.
    Giebing G; Tölle M; Jürgensen J; Eichhorst J; Furkert J; Beyermann M; Neuschäfer-Rube F; Rosenthal W; Zidek W; van der Giet M; Oksche A
    Circ Res; 2005 Sep; 97(7):707-15. PubMed ID: 16141412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents.
    Camarda V; Rizzi A; Calò G; Gendron G; Perron SI; Kostenis E; Zamboni P; Mascoli F; Regoli D
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):141-9. PubMed ID: 11819032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urotensin II evokes neurotransmitter release from rat cerebrocortical slices.
    Ono T; Kawaguchi Y; Kudo M; Kushikata T; Hashiba E; Yoshida H; Kudo T; Furukawa K; Douglas SA; Guerrini R; Calo' G; Hirota K
    Neurosci Lett; 2008 Aug; 440(3):275-9. PubMed ID: 18572318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo.
    Behm DJ; Aiyar NV; Olzinski AR; McAtee JJ; Hilfiker MA; Dodson JW; Dowdell SE; Wang GZ; Goodman KB; Sehon CA; Harpel MR; Willette RN; Neeb MJ; Leach CA; Douglas SA
    Br J Pharmacol; 2010 Sep; 161(1):207-28. PubMed ID: 20718751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.